Augmenting Response to Entecavir Using a Temporary Peginterferon Alpha-2a Add-on Strategy for the Treatment of HBeAg-Positive Chronic Hepatitis B.
Phase of Trial: Phase IV
Latest Information Update: 11 Nov 2014
At a glance
- Drugs Entecavir (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms ARES
- 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Nov 2012 Interim results for 160 patients at 48 weeks presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases.
- 12 Jul 2011 Planned end date changed from May 2013 to Sep 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History